Hantz Financial Services’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $57K | Buy |
108
+44
| +69% | +$23.2K | ﹤0.01% | 930 |
|
|
2025
Q1 | $41K | Sell |
64
-9
| -12% | -$5.77K | ﹤0.01% | 733 |
|
|
2024
Q4 | $52K | Hold |
73
| – | – | ﹤0.01% | 660 |
|
|
2024
Q3 | $77K | Buy |
73
+34
| +87% | +$35.9K | ﹤0.01% | 629 |
|
|
2024
Q2 | $41K | Buy |
39
+5
| +15% | +$5.26K | ﹤0.01% | 678 |
|
|
2024
Q1 | $33K | Hold |
34
| – | – | ﹤0.01% | 697 |
|
|
2023
Q4 | $30K | Hold |
34
| – | – | ﹤0.01% | 693 |
|
|
2023
Q3 | $28K | Sell |
34
-23
| -40% | -$18.9K | ﹤0.01% | 690 |
|
|
2023
Q2 | $41K | Sell |
57
-33
| -37% | -$23.7K | ﹤0.01% | 641 |
|
|
2023
Q1 | $74K | Hold |
90
| – | – | ﹤0.01% | 590 |
|
|
2022
Q4 | $65K | Sell |
90
-31
| -26% | -$22.4K | ﹤0.01% | 595 |
|
|
2022
Q3 | $83K | Sell |
121
-12
| -9% | -$8.23K | ﹤0.01% | 564 |
|
|
2022
Q2 | $79K | Sell |
133
-30
| -18% | -$17.8K | ﹤0.01% | 565 |
|
|
2022
Q1 | $114K | Sell |
163
-188
| -54% | -$131K | ﹤0.01% | 563 |
|
|
2021
Q4 | $222K | Buy |
351
+139
| +66% | +$87.9K | 0.01% | 501 |
|
|
2021
Q3 | $128K | Sell |
212
-3
| -1% | -$1.81K | ﹤0.01% | 523 |
|
|
2021
Q2 | $120K | Sell |
215
-84
| -28% | -$46.9K | ﹤0.01% | 503 |
|
|
2021
Q1 | $141K | Sell |
299
-24,961
| -99% | -$11.8M | 0.01% | 464 |
|
|
2020
Q4 | $12.2M | Buy |
25,260
+777
| +3% | +$375K | 0.55% | 44 |
|
|
2020
Q3 | $13.7M | Buy |
24,483
+1,136
| +5% | +$636K | 0.7% | 31 |
|
|
2020
Q2 | $14.6M | Buy |
23,347
+1,125
| +5% | +$702K | 0.81% | 26 |
|
|
2020
Q1 | $10.9M | Buy |
+22,222
| New | +$10.9M | 0.75% | 28 |
|